Nearly half of 100 vulnerable medicines have at least one key starting material sourced exclusively from one country, ...
Individualized compounding enables precise dose adjustments, alternative dosage forms, and allergen/excipient avoidance for ...
In today’s Pharmaceutical Executive Daily, UnitedHealth raises its full-year profit forecast following stronger-than-expected ...
Documented AI productivity gains include 28% faster target identification, 22% faster biomarker identification, and 20% ...
Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...
Adjusted EPS was $7.23, materially ahead of expectations, and 2026 adjusted EPS guidance was raised to >$18.25, aided by ...
Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...
In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump ...
“We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental ...
The deal secures Lilly an in vivo gene therapy platform that could make CAR-T cell therapies accessible to a far broader ...
A meaningful US access gap persists for off-patent biologics lacking viable biosimilar programs, especially mid-tier products ...
Model N’s Michael Grosberg breaks down the accelerated complexity, policy disruption, and data gaps testing manufacturer market access and revenue management strategies. In the debut episode ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results